Abdominal myomectomy versus uterine @entity887 in the treatment of symptomatic uterine XXXX .

@entity1 @entity887 @entity158 @entity931 @entity2909
OBJECTIVE: The purpose of this study was to compare treatment efficacy and complications of abdominal myomectomy with those of uterine @entity887 in @entity1 with symptomatic uterine fibroids. MATERIALS AND METHODS: We analyzed the outcomes of 111 consecutive @entity1 who underwent abdominal myomectomy (n = 44) or @entity887 (n = 67) over a 30-month period. The mean ages of the two groups were 37.7 years (range, 28-48 years) and 44.2 years (range, 31-56 years), respectively. A questionnaire and review of medical records assessed all procedure-related complications and changes in symptoms. Length of hospital stay, time until resumption of daily activities, and @entity158 medication requirements after the procedure were also analyzed. RESULTS: Follow-up times for the myomectomy and embolization groups were 14.6 and 14.3 months, respectively. The respective observed success rates in abdominal myomectomy and uterine @entity887 @entity1 were 64% versus 92% for @entity931 (p < 0.05), 54% versus 74% for @entity158 (not significant), and 91% versus 76% for mass effect (p < 0.05). The complication rates were 25% (abdominal myomectomy) and 11% (uterine @entity887 ) (p < 0.05). The respective secondary end points for the two procedures were 2.9 versus 0 days mean hospital stay, 8.7 versus 5.1 days of narcotics use, and 36 versus 8 days until resumption of normal activities. These differences were all statistically significant. CONCLUSION: Uterine @entity887 is a less invasive and safer treatment option in @entity1 with symptomatic @entity2909 than myomectomy. @entity931 may be better controlled with embolization, and myomectomy may be a better option in @entity1 with mass effect. Both procedures were equally effective in controlling @entity158 .
